IL-10 Differentially Promotes Mast Cell Responsiveness to IL-33, Resulting in Enhancement of Type 2 Inflammation and Suppression of Neutrophilia.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
18 Mar 2024
Historique:
received: 21 12 2023
accepted: 26 02 2024
medline: 18 3 2024
pubmed: 18 3 2024
entrez: 18 3 2024
Statut: aheadofprint

Résumé

Mast cells (MCs) play critical roles in the establishment of allergic diseases. We recently demonstrated an unexpected, proinflammatory role for IL-10 in regulating MC responses. IL-10 enhanced MC activation and promoted IgE-dependent responses during food allergy. However, whether these effects extend to IgE-independent stimuli is not clear. In this article, we demonstrate that IL-10 plays a critical role in driving IL-33-mediated MC responses. IL-10 stimulation enhanced MC expansion and degranulation, ST2 expression, IL-13 production, and phospho-relA upregulation in IL-33-treated cells while suppressing TNF-α. These effects were partly dependent on endogenous IL-10 and further amplified in MCs coactivated with both IL-33 and IgE/Ag. IL-10's divergent effects also extended in vivo. In a MC-dependent model of IL-33-induced neutrophilia, IL-10 treatment enhanced MC responsiveness, leading to suppression of neutrophils and decreased TNF-α. In contrast, during IL-33-induced type 2 inflammation, IL-10 priming exacerbated MC activity, resulting in MC recruitment to various tissues, enhanced ST2 expression, induction of hypothermia, recruitment of eosinophils, and increased MCPT-1 and IL-13 levels. Our data elucidate an important role for IL-10 as an augmenter of IL-33-mediated MC responses, with implications during both allergic diseases and other MC-dependent disorders. IL-10 induction is routinely used as a prognostic marker of disease improvement. Our data suggest instead that IL-10 can enhance ST2 responsiveness in IL-33-activated MCs, with the potential to both aggravate or suppress disease severity depending on the inflammatory context.

Identifiants

pubmed: 38497670
pii: 266770
doi: 10.4049/jimmunol.2300884
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : HHS | National Institutes of Health (NIH)
ID : AI167884-01A1
Organisme : HHS | National Institutes of Health (NIH)
ID : AI107668

Informations de copyright

Copyright © 2024 by The American Association of Immunologists, Inc.

Auteurs

Saurav Ranjitkar (S)

Department of Nutritional Sciences, University of Connecticut, Storrs, CT.

Dylan Krajewski (D)

Department of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.

Chelsea Garcia (C)

Department of Nutritional Sciences, University of Connecticut, Storrs, CT.

Caitlin Tedeschi (C)

Department of Nutritional Sciences, University of Connecticut, Storrs, CT.

Stephanie H Polukort (SH)

Department of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.

Jeffrey Rovatti (J)

Department of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.

Mohamed Mire (M)

Department of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.

Christopher N Blesso (CN)

Department of Nutritional Sciences, University of Connecticut, Storrs, CT.

Evan Jellison (E)

Department of Immunology, University of Connecticut, Farmington, CT.

Sallie S Schneider (SS)

Pioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield, MA.

John J Ryan (JJ)

Department of Biology, Virginia Commonwealth University, Richmond, VA.

Clinton B Mathias (CB)

Department of Nutritional Sciences, University of Connecticut, Storrs, CT.

Classifications MeSH